Last reviewed · How we verify
NCT03664895
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
Phase 3 trial testing Leuplin or zoladex in Breast Cancer Invasive in 224 participants. Status unknown.
2 December 2024
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 224 |
| Start date | 3 September 2018 |
| Primary completion | 2 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Leuplin or zoladex — full drug profile →
Conditions studied
- Breast Cancer Invasive — all drugs for Breast Cancer Invasive →
Sponsor
Seoul National University Hospital
Who can join
Adults 20 to 45, female only, with Breast Cancer Invasive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
DELFINO tial is designed to investigate the role of "OFS add on to TMX ", based on MMG density as a surrogate marker in premenopausal women * Premise - MMG density as a surrogate marker of hormone therapy * Assumption - "Add on OFS to TMX" would have further decrease of density * 3-arm(Observation arm + Randomised 2-arm), phase III, RCT with 1:1 allocation
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03664895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Invasive
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07283718 — The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis · active not recruiting
- NCT06958991 — Confocal Histolog Scanner in Routine Breast-Conserving Surgery (CHiB) · NA · recruiting
- NCT06807502 — Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device · NA · recruiting
- NCT06781281 — NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03664895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 4 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03664895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing